673 related articles for article (PubMed ID: 15086694)
1. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
2. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
4. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C; Stafford RS; Alexander GC
Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
[TBL] [Abstract][Full Text] [Related]
5. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Fenn GC; Grobler M; Schaffer D
Intern Med J; 2004 Nov; 34(11):647-9; discussion 650. PubMed ID: 15546461
[No Abstract] [Full Text] [Related]
6. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
Schneeweiss S; Glynn RJ; Avorn J; Solomon DH
J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677
[TBL] [Abstract][Full Text] [Related]
7. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
8. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
9. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
Barozzi N; Tett SE
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
[TBL] [Abstract][Full Text] [Related]
10. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors.
Behan K; Cutts C; Tett SE
J Clin Pharm Ther; 2005 Aug; 30(4):337-43. PubMed ID: 15985047
[TBL] [Abstract][Full Text] [Related]
11. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
Lanas A
Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
[TBL] [Abstract][Full Text] [Related]
14. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal antiinflammatory drug use among patients with GI bleeding.
Dominick KL; Bosworth HB; Jeffreys AS; Grambow SC; Oddone EZ; Horner RD
Ann Pharmacother; 2004; 38(7-8):1159-64. PubMed ID: 15187205
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors. What is their place?
McGettigan P
Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
[TBL] [Abstract][Full Text] [Related]
17. Inadequate prevention of NSAID-induced gastrointestinal events.
Herings RM; Goettsch WG
Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
[TBL] [Abstract][Full Text] [Related]
18. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
19. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
20. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
